OXFORD, UK I 19, 2024 I Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has dosed the first ...
GIGA-2339 contains more than 1,000 fully human recombinant anti-HBV antibodies and is the first recombinant polyclonal therapeutic in development to treat and ...
Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 ...
NKTR-422 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions - ...
MELBOURNE, Australia I 19, 2024 I Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces it will expand its ...
Neurizon’s lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR DNA-binding protein 43 (TDP-43) by ~50% and ~55% respectively, in M337V ...
SHANGHAI, China I 19, 2024 I Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, ...
Investigational subcutaneous pembrolizumab and berahyaluronidase alfa, in combination with chemotherapy, demonstrates noninferior pharmacokinetics compared to intravenous KEYTRUDA in combination with ...
PRINCETON, NJ, USA & TOKYO, Japan I November 19, 2024 I Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) announce the decision to submit ...
REDWOOD CITY, CA & BOSTON, MA, USA I 18, 2024 I Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for ...
Preclinical data shows strong, durable, and precise repression of HBV DNA across in vitro and in vivo models, offering a possible pathway to a functional cure ...
The UVAX-1107 protein nanoparticle vaccine was safe and well-tolerated in healthy volunteers at the planned Interim Analysis #1 ...